Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders...

CLSN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company") securities between November 2, 2015 and July 10, 2020 (the "Class Period"). The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose: (1) defendants had significantly overstated the efficacy of...

SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Celsion Investors and Encourages Investors With Significant Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Celsion investors under the federal securities laws. To join the Celsion class action, go to http://www.rosenlegal.com/cases-register-1978.html or call Phillip Kim, Esq. toll-fr

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Celsion Corporation – CLSN

NEW YORK--(BUSINESS WIRE)-- #Celsion--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Celsion Corporation (NASDAQ: CLSN) securities between November 2, 2015 to July 10, 2020 (the “Class Period”). Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click h

CELSION ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celsion Corporation and Encourages Investors to Contact the Firm

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey,...

Pomerantz Law Firm Announces the Filing of a Class Action against Celsion Corporation Certain Officers - CLSN

CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies

Celsion Corporation Issues Letter to Stockholders

Agreement Includes 1 Million Shares Purchased at 28% Market Premium

Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study

Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization

Celsion Corporation Restructures its Strategic Loan Facility

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2020 Results - Earnings Call Transcript

Shares of Celsion (NASDAQ:CLSN) rose 2% in pre-market trading after the company reported Q2 results.

Celsion: Q2 Earnings Insights

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system and ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin at 11:00 a.m. EDT on Friday, August 14, 2020.

Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020

Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients

Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer

Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.

Celsion Down on DMC Recommendation to Stop Liver Cancer Study

LAWRENCEVILLE, N.J., July  14, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Company’s next steps.

Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time

Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival

Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study

LAWRENCEVILLE, N.J, June  25, 2020  (GLOBE NEWSWIRE) --    Celsion Corporation    (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the second pre-planned interim safety and efficacy analysis of the Phase III OPTIMA Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Members of the iDMC represent the global market for HCC and are based in the U.S., Canada and Europe, and Celsion believes that any logistical challenges to the Committee’s performing its work presented by the global COVID-19 pandemic have been addressed. Celsion expects to announce the iDMC’s recommendations and Company next steps soon after the meeting concludes.

Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

Lawrenceville, NJ, June  24, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds of $9.3 million, after deducting underwriting discounts and commissions but before expenses payable by the Company.

Celsion Corporation Announces Closing of Public Offering of Common Stock

Lawrenceville, NJ, June  22, 2020  (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering price of $3.75 per share, less underwriting discounts and commission. The gross proceeds from the offering will be $10 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares of common stock are being sold to both existing and new institutional investors of the Company. The offering is expected to close on June 24, 2020, subject to satisfaction of customary closing conditions.

Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock

 Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose

Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to  Phase II of the OVATION 2 Study in Advanced Ovarian Cancer

Celsion: Big Gains Possible In July

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2020 Results - Earnings Call Transcript

Phase III OPTIMA Study on Track for Interim Data Analysis in July

News for Celsion Stock (CLSN)